Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY) (NYSE:RDY) on Wednesday announced the availability in the US of Sapropterin Dihydrochloride Powder for Oral Solution in 100 mg.
The company added that Sapropterin Dihydrochloride Powder for Oral Solution in 100 mg is a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the US Food and Drug Administration (USFDA).
According to the company, Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.
KUVAN (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution are prescription medicines used to lower blood Phe levels in adults and children over one month of age with a certain type of Phenylketonuria (PKU), a genetic condition that causes increased levels of phenylalanine (an amino acid) in the body, concluded the company.
Campanelli Named to Slayback Board of Directors
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market
Dr. Reddy's Laboratories Launches Capecitabine Tablets, USP in the US Market
Dr Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets, USP in US antipsychotic market
Akorn Operating's Loteprednol Etabonate Ophthalmic Gel, 0.5% receives US FDA approval
Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
Sandoz introduces generic Icatibant injection pre-filled syringe in US
Xspray Pharma commences study with modified formulation of HyNap-Dasa
CONTINUUS Pharmaceuticals receives USD69.3m US government contract
Sputnik V Meets Primary Endpoint of Safety in India Phase 2 Clinical Trial
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA